Y-mAbs Therapeutics, Inc. Common Stock (YMAB) is a publicly traded Healthcare sector company. As of October 12, 2026, YMAB trades at $8.61 with a market cap of $391.22M and a P/E ratio of -17.22. YMAB moved +0.23% today. Year to date, YMAB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $3.55 to $8.61. Analyst consensus is buy with an average price target of $12.71. Rallies surfaces YMAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Y-mAbs Therapeutics, Inc. Common Stock (YMAB) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. YMAB moved +0.23% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $8.61 |
| Market Cap | $391.22M |
| P/E Ratio | -17.22 |
| EPS | $-0.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.61 |
| 52-Week Low | $3.55 |
| Volume | 760.67K |
| Avg Volume | 0 |
| Revenue (TTM) | $85.39M |
| Net Income | $-22.22M |
| Gross Margin | 81.78% |
16 analysts cover YMAB: 0 strong buy, 8 buy, 6 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.71.